Biotechnology CEO Clay Siegall

Dr. Siegall helped to establish Seattle Genetics in 1998 and is the organization’s President, Chief Executive Officer and Chairman of the Board of Directors. Under his authority, Seattle Genetics has fabricated a differing pipeline of neutralizer based malignancy treatments, including ADCETRIS (brentuximab vedotin) that was allowed quickened endorsement by the U.S. Sustenance and Drug Administration (FDA) in 2011.

Dr. Siegall has additionally guided Seattle Genetics/capital-raising exercises, securing more than $675 million through open and private financings, including the organization’s first sale of stock in 2001. Before helping to establish Seattle Genetics, Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997 and the National Cancer Institute, National Institutes of Health from 1988 to 1991. He serves on the Board of Directors of Alder BioPharmaceuticals, a private biotechnology organization. Dr. Siegall is a creator on more than 70 productions and holds 15 licenses. He got a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland.

Under Dr. Siegall’s authority, Seattle Genetics has gone into various vital licenses for its ADC innovation, incorporating with Genentech (Roche), AbbVie, GlaxoSmithKline and Pfizer, that have produced more than $350 million to date. Crosswise over inside and partner programs, there are more than 20 ADCs in clinical improvement utilizing Seattle Genetics’ innovation. Dr. Siegall has additionally driven Seattle Genetics’ capital-raising exercises, securing more than $1.2 billion through open and private financings, including the organization’s first sale of stock in 2001.

Before helping to establish Seattle Genetics, Dr. Clay  Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997 and the National Cancer Institute, National Institutes of Health from 1988 to 1991. He serves on the Boards of Directors of Ultragenyx Pharmaceutical, Alder BioPharmaceuticals and Washington Roundtable. Dr. Siegall has been the beneficiary of various honors, including the 2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences, and the 2012 Pacific Northwest Ernst and Young Entrepreneur of the Year.